


Cortellis Competitive Intelligence™ 應用案例


如何快速預測藥物取得藥證的成功率及預計時間

1. 登入 Cortellis 後，在 ①處輸入目標藥物名稱，以“pacritinib”為例，點擊 ② “Index” 按鈕，獲取藥物清單。點擊 ③處進入藥物獲證成功率和時程預測模組。




Drug Name	Active Companies	Therapy Area	Active Indications	Target-based Actions
pacritinib	CTI BioPharma Corp	Respiratory; Immune; Infection; Cancer; Hematologic	Chronic lymphocytic leukemia; Coronavirus disease 19 infection; Graft versus host disease; Myelofibrosis;	CSF-1 antagonist; Cytochrome P450 reductase inhibitor; FIt3 tyrosine kinase inhibitor; IRAK-1 protein kinase inhibitor;

2. 點擊 ④處勾選該藥物，再點擊 ⑤處預測按鈕。



Company	Indication	Development Status	Region / Country	Date	Regulatory Designation
CTI BioPharma Corp	Chronic lymphocytic leukemia	Phase 2 Clinical	US	17-Feb-2016	
CTI BioPharma Corp	Graft versus host disease	Phase 2 Clinical	US	30-Mar-2017	

3. 點擊 ⑥處  中間的按鈕切換為賽馬圖，可查看 pacritinib 在各適應症的上市時程和成功率比較。

Select all drugs

Actual Date
 Predicted Date
 Completed Phase
 Predicted Phase
 Phase Probability of Success
 Prediction Interval
 Milestone
 Milestone Range
 Change View:

pacritinib

Company: CTI BioPharma Corp Indication: Thrombocytopenia Regulatory Designation: Accelerated Approval Region / Country: US

Time to Registration: 3.9 years
Probability of success:

Change View:

Drug name	Time to Registration (Years)	Probability of Success
pacritinib Thrombocytopenia US	Phase 3 — 3.9	90%
pacritinib Graft versus host disease US	Phase 2 — 3.7	15%
pacritinib Chronic lymphocytic leukemia US	Phase 2 — 3.4	16%

REGISTRATION

科睿唯安 台灣辦公室

台北市信義區松智路 1 號 11 樓

客戶支援專線：0080 149 1138

客戶支援信箱：ts.support.asia@clarivate.com

clarivate.com